Purpose: To compare the outcomes of fluorescein angiography (FA)-guided and indocyanine green angiography (ICGA)-guided half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (CSC).

Methods: In this retrospective comparative study, medical records of eyes with chronic CSC who underwent half-dose PDT were reviewed. A retina specialist performed FA-guided half-dose PDT, and the other performed ICGA-guided treatment. The success of applying PDT in the resolution of subretinal fluid was compared between the FA- and ICGA-guided methods.

Results: Eighty-two eyes of 73 patients (41 eyes in each group) received half-dose PDT. After half-dose PDT, a significant improvement in the best-corrected visual acuity (BCVA) was found at the time of the last follow-up in both groups (both P < 0.001), with no significant intergroup difference. Central subfield and subfoveal choroidal thicknesses decreased significantly in both groups at the last follow-up (all P < 0.05), with no significant differences between the groups. Subretinal fluid (SRF) resolved in all eyes, and no persistent SRF was detected during the follow-up period.

Conclusion: FA-guided and ICG-guided half-dose PDT may have similar efficacy for the treatment of chronic CSC.

Central Serous Chorioretinopathy, Fluorescein Angiography, Indocyanine Green Angiography, Photodynamic Therapy

2. van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res 2019;73:100770.

3. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015;48:82–118.

4. Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: Available treatment options. Eye 2019;33:1035–1043.

5. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: Photodynamic therapy. Am J Ophthalmol 2004;137:1073–1080.

6. Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye 2014;28:944–957.

7. Altinel MG, Kanra AY, Totuk OMG, Ardagil A, Kabadayi K. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy. Photodiagnosis Photodyn Ther 2021;33:102081.

8. Naseripour M, Falavarjani KG, Sedaghat A, Moghaddam AK, Nasserisina S, Alemzadeh SA. Half-dose photodynamic therapy for chronic central serous chorioretinopathy. J Ophthalmic Vis Res 2016;11:66–69.

9. Viana KÍ S, Leão PMS, Fernandes L, Siqueira R, Ribeiro J, Jorge R. Multimodal assessment of patients with chronic central serous chorioretinopathy. Arq Bras Oftalmol 2017;80:181–185.

10. Koytak A, Bayraktar H, Ozdemir H. Fluorescein angiography as a primary guide for reduced-fluence photodynamic therapy for the treatment of chronic central serous chorioretinopathy. Int Ophthalmol 2020;40:1807–1813.

11. Hayashida M, Miki A, Honda S, Nakamura M. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Photodiagnosis Photodyn Ther. 2020;31:101955.

12. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752–763.

13. Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2014;157:1033– 1037.

14. Liu HY, Yang CH, Yang CM, Ho TC, Lin CP, Hsieh YT. Half-dose versus half-time photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 2016;167:57–64.

15. van Dijk EHC, van Rijssen TJ, Subhi Y, Boon CJF. Photodynamic therapy for chorioretinal diseases: A practical approach. Ophthalmol Ther 2020;9:329–342.

16. Newman DK. Photodynamic therapy: Current role in the treatment of chorioretinal conditions. Eye 2016;30:202–210.

17. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996;103:2070–2079; discussion 9–80.

18. Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, et al. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 2015;122:555–561.

19. Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: One-year results of a prospective study. Retina 2008;28:85–93.

20. Koytak A, Erol K, Coskun E, Asik N, Öztürk H, Özertürk Y. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 2010;30:1698–1703.

21. Ebrahimiadib N, Mirzaei A, Esfandiarifard S, Tuli S, Najibzadeh E, Imani Fooladi M, et al. Comparison of the fluorescein angiography-guided and indocyanine green angiography-guided photodynamic therapy in the treatment of non-resolving central serous chorioretinopathy. Sci Rep 2023;13:1682.